Cargando…

Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Acute exacerbation is a major cause of morbidity and mortality in patients with idiopathic pulmonary fibrosis. Although the real nature of it is still not clear and there is no proven effective therapy, progress has been made since the consensus definition and diagnostic criteria were proposed. The...

Descripción completa

Detalles Bibliográficos
Autor principal: Kim, Dong Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157478/
http://dx.doi.org/10.1016/B978-0-12-801238-3.11454-0
_version_ 1783522351380430848
author Kim, Dong Soon
author_facet Kim, Dong Soon
author_sort Kim, Dong Soon
collection PubMed
description Acute exacerbation is a major cause of morbidity and mortality in patients with idiopathic pulmonary fibrosis. Although the real nature of it is still not clear and there is no proven effective therapy, progress has been made since the consensus definition and diagnostic criteria were proposed. The trial results of several new innovative therapies in idiopathic pulmonary fibrosis have suggested a potential for benefit in acute exacerbation of idiopathic pulmonary fibrosis, leading to double blind randomized clinical trials in this area. This article reviews the present knowledge on acute exacerbation of idiopathic pulmonary fibrosis, focusing on the triggering factors and treatment.
format Online
Article
Text
id pubmed-7157478
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-71574782020-04-15 Acute Exacerbation of Idiopathic Pulmonary Fibrosis Kim, Dong Soon Encyclopedia of Respiratory Medicine Article Acute exacerbation is a major cause of morbidity and mortality in patients with idiopathic pulmonary fibrosis. Although the real nature of it is still not clear and there is no proven effective therapy, progress has been made since the consensus definition and diagnostic criteria were proposed. The trial results of several new innovative therapies in idiopathic pulmonary fibrosis have suggested a potential for benefit in acute exacerbation of idiopathic pulmonary fibrosis, leading to double blind randomized clinical trials in this area. This article reviews the present knowledge on acute exacerbation of idiopathic pulmonary fibrosis, focusing on the triggering factors and treatment. 2022 2021-09-17 /pmc/articles/PMC7157478/ http://dx.doi.org/10.1016/B978-0-12-801238-3.11454-0 Text en Copyright © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kim, Dong Soon
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
title Acute Exacerbation of Idiopathic Pulmonary Fibrosis
title_full Acute Exacerbation of Idiopathic Pulmonary Fibrosis
title_fullStr Acute Exacerbation of Idiopathic Pulmonary Fibrosis
title_full_unstemmed Acute Exacerbation of Idiopathic Pulmonary Fibrosis
title_short Acute Exacerbation of Idiopathic Pulmonary Fibrosis
title_sort acute exacerbation of idiopathic pulmonary fibrosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157478/
http://dx.doi.org/10.1016/B978-0-12-801238-3.11454-0
work_keys_str_mv AT kimdongsoon acuteexacerbationofidiopathicpulmonaryfibrosis